Melissa J Blumenthal1,2, Charlotte Schutz2,3,4, David Barr4,5, Michael Locketz6, Vickie Marshall7, Denise Whitby7, Arieh A Katz1,2, Thomas Uldrick8, Graeme Meintjes2,3,4, Georgia Schäfer1,2. 1. Division of Medical Biochemistry and Structural Biology, Department of Integrative Biomedical Sciences. 2. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa. 3. Department of Medicine, University of Cape Town, South Africa. 4. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, South Africa. 5. Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Institute of Infection and Global Health, University of Liverpool, United Kingdom. 6. Division of Anatomical Pathology, National Health Laboratory Service, University of Cape Town, South Africa. 7. Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, National Institutes of Health, Maryland. 8. Fred Hutchison Cancer Research Center, Seattle, Washington.
Abstract
BACKGROUND: Despite increasing numbers of human immunodeficiency virus (HIV)-infected South Africans receiving antiretroviral therapy (ART), tuberculosis (TB) remains the leading cause of mortality. Approximately 25% of patients treated for TB have microbiologically unconfirmed diagnoses. We assessed whether elevated Kaposi's sarcoma-associated herpesvirus (KSHV) viral load (VL) contributes to mortality in hospitalized HIV-infected patients investigated for TB. METHODS: Six hundred eighty-two HIV-infected patients admitted to Khayelitsha Hospital, South Africa, were recruited, investigated for TB, and followed for 12 weeks. KSHV serostatus, peripheral blood KSHV-VL, and KSHV-associated clinical correlates were evaluated. RESULTS: Median CD4 count was 62 (range, 0-526) cells/μL; KSHV seropositivity was 30.7% (95% confidence interval [CI], 27%-34%); 5.8% had detectable KSHV-VL (median, 199.1 [range, 13.4-2.2 × 106] copies/106 cells); 22% died. Elevated KSHV-VL was associated with mortality (adjusted odds ratio, 6.5 [95% CI, 1.3-32.4]) in patients without TB or other microbiologically confirmed coinfections (n = 159). Six patients had "possible KSHV-inflammatory cytokine syndrome" (KICS): 5 died, representing significantly worse survival (P < .0001), and 1 patient was diagnosed with KSHV-associated multicentric Castleman disease at autopsy. CONCLUSIONS: Given the association of mortality with elevated KSHV-VL in critically ill HIV-infected patients with suspected but not microbiologically confirmed TB, KSHV-VL and KICS criteria may guide diagnostic and therapeutic evaluation.
BACKGROUND: Despite increasing numbers of human immunodeficiency virus (HIV)-infected South Africans receiving antiretroviral therapy (ART), tuberculosis (TB) remains the leading cause of mortality. Approximately 25% of patients treated for TB have microbiologically unconfirmed diagnoses. We assessed whether elevated Kaposi's sarcoma-associated herpesvirus (KSHV) viral load (VL) contributes to mortality in hospitalized HIV-infectedpatients investigated for TB. METHODS: Six hundred eighty-two HIV-infectedpatients admitted to Khayelitsha Hospital, South Africa, were recruited, investigated for TB, and followed for 12 weeks. KSHV serostatus, peripheral blood KSHV-VL, and KSHV-associated clinical correlates were evaluated. RESULTS: Median CD4 count was 62 (range, 0-526) cells/μL; KSHV seropositivity was 30.7% (95% confidence interval [CI], 27%-34%); 5.8% had detectable KSHV-VL (median, 199.1 [range, 13.4-2.2 × 106] copies/106 cells); 22% died. Elevated KSHV-VL was associated with mortality (adjusted odds ratio, 6.5 [95% CI, 1.3-32.4]) in patients without TB or other microbiologically confirmed coinfections (n = 159). Six patients had "possible KSHV-inflammatory cytokine syndrome" (KICS): 5 died, representing significantly worse survival (P < .0001), and 1 patient was diagnosed with KSHV-associated multicentric Castleman disease at autopsy. CONCLUSIONS: Given the association of mortality with elevated KSHV-VL in critically ill HIV-infectedpatients with suspected but not microbiologically confirmed TB, KSHV-VL and KICS criteria may guide diagnostic and therapeutic evaluation.
Authors: P Monini; S Colombini; M Stürzl; D Goletti; A Cafaro; C Sgadari; S Buttò; M Franco; P Leone; S Fais; P Leone; G Melucci-Vigo; C Chiozzini; F Carlini; G Ascherl; E Cornali; C Zietz; E Ramazzotti; F Ensoli; M Andreoni; P Pezzotti; G Rezza; R Yarchoan; R C Gallo; B Ensoli Journal: Blood Date: 1999-06-15 Impact factor: 22.113
Authors: T B Campbell; M Borok; L Gwanzura; S MaWhinney; I E White; B Ndemera; I Gudza; L Fitzpatrick; R T Schooley Journal: AIDS Date: 2000-09-29 Impact factor: 4.177
Authors: J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos Journal: Blood Date: 1995-08-15 Impact factor: 22.113
Authors: Satish Gopal; N George Liomba; Nathan D Montgomery; Agnes Moses; Bongani Kaimila; Richard Nyasosela; Maria Chikasema; Bal M Dhungel; Coxcilly Kampani; Marcia K Sanders; Robert Krysiak; Dirk P Dittmer; Yuri Fedoriw Journal: J Int AIDS Soc Date: 2015-08-03 Impact factor: 5.396